Landmark papers
NEJM 2015 — Pembrolizumab vs. ipilimumab establishing modern first-line care.
JCO 2023 — Seven-year KEYNOTE-006 follow-up proving long-term survival.
Cancer Journal 2015 — Israeli TIL experience demonstrating 50% response rates.
Active trials
Reduced-intensity lymphodepletion studies, uveal melanoma combinations, and ongoing recruitment for next-generation adoptive cell strategies.
- NCT03412526 – Reduced-intensity lymphodepletion + adoptive cell therapy.
- SUMIT – Selumetinib with dacarbazine for metastatic uveal melanoma.
- Predictors of TIL efficacy – identifying biomarkers for durable control.
Key references are linked across Ella Institute publications, ClinicalTrials.gov, and peer-reviewed archives.
Reference library
Source material spans institutional profiles, peer-reviewed journals, clinical trial registries, and media briefings.